A phase I/II, multicentre clinical study of ZD1839 (Iressa (TM)) in combination with capecitabine (Xeloda) in subjects with advanced colorectal carcinoma after failure of first-line chemotherapy.

Trial Profile

A phase I/II, multicentre clinical study of ZD1839 (Iressa (TM)) in combination with capecitabine (Xeloda) in subjects with advanced colorectal carcinoma after failure of first-line chemotherapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2009

At a glance

  • Drugs Capecitabine; Gefitinib
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Dec 2007 Status changed from in progress to completed.
    • 24 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top